Post-earnings recap
Reported
Mon, May 2, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a wider-than-expected loss in EPS, which contributed to a 2.53% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term outlook. Management's defensive tone suggests they are aware of the challenges ahead but are committed to long-term strategies.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | -19.50% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current performance but remains focused on future growth. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term goals despite short-term setbacks.